drugset

drugset / Trial / NCT00600600

Tigecycline for Treatment of Rapidly Growing Mycobacteria

NCT00600600 ↗

Phase 2 Completed 8 enrolled The University of Texas Health Science Center at Tyler Wyeth is now a wholly owned subsidiary of Pfizer · collab

NaSingle-groupOpen-labelTreatment

Summary

To determine the safety, tolerance, and efficacy of Tigecycline when given daily to patients with rapidly growing mycobacterial disease (especially M.abscessus).

Timeline

Start: 2002-04
Primary completion: 2010-04
Completion: 2010-12

Publications

Wallace RJ Jr, Dukart G, Brown-Elliott BA, Griffith DE, Scerpella EG, Marshall B. Clinical experience in 52 patients with tigecycline-containing regimens for salvage treatment of Mycobacterium abscessus and Mycobacterium chelonae infections. J Antimicrob Chemother. 2014 Jul;69(7):1945-53. doi: 10.1093/jac/dku062. Epub 2014 Mar 14.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tigecycline	Small molecule	—	—

Indications